“National Research and Training Program for Technologies in Oncology” 2000-2003, MURST, Theme XI “Identification of molecules involved in the immune response and evaluation of their po#273949E
Project objectivesTraining program:
Research program: The research program includes the development of a prototype multigene plasmid vector that allows the simultaneous expression of multiple coding regions in eukaryotic systems. This vector is constructed by optimizing and assembling regulatory and coding sequences into a newly developed plasmid. In this first phase, a prototype vector specific for DNA vaccination is being constructed, which will serve as a model for subsequent studies. Based on this prototype vector, vectors are then generated that express immunostimulatory molecules and specific antigens, along with regulatory sequences for gene expression and/or antigen processing and/or immunostimulation. These vectors also contain regulatory sequences for eukaryotic gene expression. Plasmid vectors are designed to include all the sequences necessary for gene expression and immunomodulation. This strategy leads to the construction of multigene and/or polycistronic vectors by incorporating two or more transcriptional units and/or ribosomal binding sites (RBSs) to introduce multiple translation starts. The study is conducted using existing vectors and newly constructed plasmids. Specifically, studies have already been conducted to construct vaccination-specific plasmid vectors, which constitute a useful starting point for the development of new vectors dedicated to this project (construction of a prototype family of immunotherapy-specific plasmid vectors by incorporating two autonomous transcriptional units for the co-expression of an immunomodulatory cytokine and the selected antigen, and description of a method for the expression of short gene sequences encoding the specific hapten). |
Start and end date |
|
15/01/2000 - 15/01/2003 |
Project Manager |
|
Prof. Vito Michele Fazio - Scientific manager |
Coordinating institution of the project |
|
Norpharma SpA |
Funding source(s). |
|
MURST |
